Table 1.
Selected engineered TCR therapy trials in solid tumor from ClinicalTrials.gov
| Target | Type of cancer | Phase | Clinical trial number |
|---|---|---|---|
| MAGEA1 | Solid tumors | I | NCT03441100 |
| MAGEA1 | Advanced solid tumors | I/II | NCT05430555 |
| MAGEA3 | Cervical cancer; Renal cancer; Urothelial cancer; Melanoma; Breast cancer | I/II | NCT02111850 |
| MAGE-A3/A6 | Solid tumors | I | NCT03139370 |
| MAGEA4/8 | Solid tumors | I | NCT03247309 |
| MAGE-C2 | Melanoma; Head and neck Cancer | I/II | NCT04729543 |
| NY-ESO-1 | Neoplasms | I | NCT01343043 |
| NY-ESO-1 | Melanoma; Meningioma; Breast Cancer; Non-Small Cell Lung Cancer; Hepatocellular Cancer | II | NCT01967823 |
| NY-ESO-1 | Multiple Myeloma | II | NCT01352286 |
| HPV-16 E7 | Metastatic or refractory/recurrent human papillomavirus (HPV)-16 + cancers | I/II | NCT02858310 |
| HBV | Hepatocellular Carcinoma | I | NCT03899415 |
| EBV | Nasopharyngeal Carcinoma | III | NCT02578641 |
| EBV | Nasopharyngeal Carcinoma | I/II | NCT04509726 |